{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:28:27Z","timestamp":1790702907483,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In Germany, several biologic therapies are available for the treatment of moderate-to-severe plaque psoriasis, with the option of exceeding recommended dosages if standard dosing does not achieve a satisfactory treatment response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To examine dose escalation in patients with biologic-treated psoriasis and its implications on the costs for German statutory health insurance (SHI).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective, noninterventional cohort study using German SHI health claims data from 2016 to 2021. Adult patients initiating biologic treatment were included in drug-specific cohorts. The odds for dose escalation, defined as the exceedance of the individually received daily dose over the maintenance dose recommended by the European product information, were compared between cohorts using multivariate logistic regression. The impact of dose escalation on SHI expenditure was analysed with a generalized linear model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The relative frequency of dose escalation varied between cohorts [range 1%, &amp;lt; 5\/92 (risankizumab) to 43%, &amp;lt; 5\/7 (infliximab)]. Compared with patients treated with risankizumab, the odds for dose escalation were statistically significantly (P &amp;lt; 0.05) higher in patients treated with all other biologic drugs except tildrakizumab. Patients with dose escalation during the maintenance phase accrued on average \u20ac6473 more in direct healthcare costs to SHI over a 1-year period compared with those without dose escalation, with statistical significance (P &amp;lt; 0.05) after controlling for differences in covariates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Compared with patients treated with other biologics, dose escalation during the maintenance phase was lowest among patients treated with risankizumab. Dose escalation was associated with higher costs and thus a higher economic burden for German SHI.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llae245","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T12:13:50Z","timestamp":1723637630000},"page":"1591-1600","source":"Crossref","is-referenced-by-count":1,"title":["Dose escalation and associated economic outcomes in patients with psoriasis treated with biologics: a retrospective analysis of German health claims data"],"prefix":"10.1093","volume":"49","author":[{"given":"Andreas","family":"Pinter","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Frankfurt , Frankfurt Am Main ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M","family":"Soliman","sequence":"additional","affiliation":[{"name":"AbbVie Inc , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina C","family":"Manz","sequence":"additional","affiliation":[{"name":"IGES Institut GmbH , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Weber","sequence":"additional","affiliation":[{"name":"IGES Institut GmbH , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ludwig","sequence":"additional","affiliation":[{"name":"InGef \u2013 Institute for Applied Health Research Berlin GmbH , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Mocek","sequence":"additional","affiliation":[{"name":"IGES Institut GmbH , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"H\u00f6er","sequence":"additional","affiliation":[{"name":"IGES Institut GmbH , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G","family":"Richter","sequence":"additional","affiliation":[{"name":"AbbVie Inc , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"2024112216163055200_llae245-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","article-title":"Definition of treatment goals for moderate to severe psoriasis: a European consensus","volume":"303","author":"Mrowietz","year":"2011","journal-title":"Arch Dermatol Res"},{"key":"2024112216163055200_llae245-B2","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"2024112216163055200_llae245-B3","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s13555-023-00927-x","article-title":"Suboptimal clinical and quality of life outcomes in patients with psoriasis undertreated with oral therapies: international physician and patient survey","volume":"13","author":"Thai","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2024112216163055200_llae245-B4","volume-title":"Plaque Psoriasis","author":"Badri","year":"2023"},{"key":"2024112216163055200_llae245-B5","doi-asserted-by":"crossref","first-page":"100171","DOI":"10.1016\/j.xjidi.2022.100171","article-title":"Impact of season and other factors on initiation, discontinuation, and switching of systemic drug therapy in patients with psoriasis: a retrospective study","volume":"3","author":"Liang","year":"2023","journal-title":"JID Innov"},{"key":"2024112216163055200_llae245-B6","first-page":"934","article-title":"[German S3-Guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm \u2013\u200c part 1: treatment goals and treatment recommendations.]","volume":"19","author":"Nast","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"2024112216163055200_llae245-B7","first-page":"504","article-title":"The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives","volume":"9","author":"Feldman","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"2024112216163055200_llae245-B8","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s13555-021-00559-z","article-title":"Dose adjustment of biologic treatments for moderate-to-severe plaque psoriasis in the real world: a systematic review","volume":"11","author":"Gambardella","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2024112216163055200_llae245-B9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s13555-021-00483-2","article-title":"Interleukin-17 and interleukin-\u200b23: a narrative review of mechanisms of action in psoriasis and associated comorbidities","volume":"11","author":"Menter","year":"2021","journal-title":"Dermatol Ther"},{"key":"2024112216163055200_llae245-B10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/dth.12160","article-title":"Factors affecting response to biologic treatment in psoriasis","volume":"27","author":"Karczewski","year":"2014","journal-title":"Dermatol Ther"},{"key":"2024112216163055200_llae245-B11","doi-asserted-by":"crossref","first-page":"e33486","DOI":"10.1371\/journal.pone.0033486","article-title":"Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy","volume":"7","author":"Brezinski","year":"2012","journal-title":"PLoS One"},{"key":"2024112216163055200_llae245-B12","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1111\/ced.15288","article-title":"Real-world dose adjustments of biologic treatments in psoriasis and their economic impact: a Swedish national population study","volume":"47","author":"Egeberg","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"2024112216163055200_llae245-B13","first-page":"583","article-title":"Economic impact of above-\u00adlabel dosing with etanercept, adalimumab, or ustekinumab in patients with psoriasis","volume":"23","author":"Feldman","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"2024112216163055200_llae245-B14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2147\/CEOR.S391413","article-title":"Systematic literature review of real-world evidence on dose escalation and treatment switching in ulcerative colitis","volume":"15","author":"Singh","year":"2023","journal-title":"Clinicoecon Outcomes Res"},{"key":"2024112216163055200_llae245-B15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.puhe.2022.02.013","article-title":"Sampling strategy, characteristics and representativeness of the InGef research database","volume":"206","author":"Ludwig","year":"2022","journal-title":"Public Health"},{"key":"2024112216163055200_llae245-B16","article-title":"Consumer price index","author":"Federal Statistical Office","year":"2019"},{"key":"2024112216163055200_llae245-B17","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"2024112216163055200_llae245-B18","article-title":"Bimzelx (Bimekizumab). European Medicines Agency","author":"European Medicines Agency","year":"2023"},{"key":"2024112216163055200_llae245-B19","article-title":"[Biologics for psoriasis: intervention in the immune system comes at a price.] Deutsche Apotheker Zeitung","author":"Winterhagen","year":"2019"},{"key":"2024112216163055200_llae245-B20","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2147\/CCID.S364640","article-title":"Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: a review of the real-world evidence","volume":"15","author":"Ruggiero","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2024112216163055200_llae245-B21","doi-asserted-by":"publisher","DOI":"10.33590\/emjallergyimmunol\/10301362","article-title":"IL-17 and -23 inhibitors for the treatment of psoriasis","author":"Batta","year":"2023","journal-title":"EMJ Allergy Immunol"},{"key":"2024112216163055200_llae245-B22","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"1","author":"Sbidian","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2024112216163055200_llae245-B23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s13555-021-00647-0","article-title":"Long-term benefit-risk profiles of treatments for moderate-to-severe plaque psoriasis: a network meta-analysis","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatol Ther"},{"key":"2024112216163055200_llae245-B24","article-title":"Dose escalation of biologic treatment in patients with moderate-to-severe psoriasis in Japan","author":"Pinter"},{"key":"2024112216163055200_llae245-B25","doi-asserted-by":"crossref","first-page":"2200869","DOI":"10.1080\/09546634.2023.2200869","article-title":"Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States","volume":"34","author":"Wu","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"2024112216163055200_llae245-B26","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1080\/13696998.2021.1937187","article-title":"Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data","volume":"24","author":"Bagel","year":"2021","journal-title":"J Med Econ"},{"key":"2024112216163055200_llae245-B27","article-title":"[Summary of product characteristics: Ilumetri 100\u2005mg\/- 200\u2005mg, solution for injection in a prefilled syringe]","author":"Almirall"},{"key":"2024112216163055200_llae245-B28","article-title":"[Summary of product characteristics: Cosentyx \u00ae 150\u2005mg\/- 300\u2005mg solution for injection in a prefilled syringe]","author":"Novartis Pharma GmbH"},{"key":"2024112216163055200_llae245-B29","article-title":"Humira, INN-adalimumab","author":"European Medicines Agency"},{"key":"2024112216163055200_llae245-B30","article-title":"Cimzia, INN-certolizumab pegol","author":"European Medicines Agency"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae245\/59341017\/llae245.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/12\/1591\/60790535\/llae245.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/12\/1591\/60790535\/llae245.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T16:17:36Z","timestamp":1732292256000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/12\/1591\/7733470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,8,14]]},"published-print":{"date-parts":[[2024,11,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae245","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,8,14]]}}}